AIM ImmunoTech Announces Closing of $8.0 Million Public Offering
OCALA, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (the “Company”), today announced the closing...
Clinical Trial
GRI Bio Reports 6-Week Interim Biomarker Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
Biomarkers at 6-week interim analysis show a positive impact on fibrogenesis, fibrolysis and potentially the initiation of a repair response...
Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China
PALI-2108 is the first and only PDE4 inhibitor designed to target terminal ileum and colon for fibrostenotic Crohn’s disease (FSCD)...
Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China
PALI-2108 is the first and only PDE4 inhibitor designed to target terminal ileum and colon for fibrostenotic Crohn’s disease (FSCD)...
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics
Acquisition strengthens Supernus’ leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS discovery...
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics
Acquisition strengthens Supernus’ leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS discovery...
InspireMD Announces the Appointment of Raymond W. Cohen to its Board of Directors
MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime...
InspireMD Announces the Appointment of Raymond W. Cohen to its Board of Directors
MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime...
Glucotrack to Exhibit at 2025 Association of Diabetes Care and Education Specialists Annual Meeting
Company to present endocrinologist perspectives on implantable CBGM technology as it advances toward US pilot studyRUTHERFORD, N.J., July 31, 2025...
Glucotrack to Exhibit at 2025 Association of Diabetes Care and Education Specialists Annual Meeting
Company to present endocrinologist perspectives on implantable CBGM technology as it advances toward US pilot studyRUTHERFORD, N.J., July 31, 2025...
InspireMD Announces Combined Financings of $58 Million
Proceeds Bolster Balance Sheet to Commercialize Recently FDA Approved Best-In-Class Carotid StentMIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc....
Oragenics Selects Southern Star Research as Clinical Research Organization for ONP-002 Phase IIa Trial
Strategic CRO Partnership Supports Operational Readiness and Initiation of Upcoming Concussion StudySARASOTA, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Oragenics,...
NetraMark to Attend Canaccord Genuity’s 45th Annual Growth Conference
TORONTO, July 31, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0)...
Vericel Reports Second Quarter 2025 Financial Results
Total Revenue Growth of 20% to $63.2 Million, with MACI Revenue Growth of 21% to $53.5 Million Gross Margin Increased...
Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025
BASKING RIDGE, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage...
Inka Health Selected by OneMedNet to Lead AI-Driven Oncology Project Using Real-World Data for External Control Arms
Reduce development timelines and costs, while improving access to life-saving treatmentsVANCOUVER, British Columbia, July 31, 2025 (GLOBE NEWSWIRE) -- Onco-Innovations...
Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Completed Merger with GlycoMimetics and Previously Announced $200 Million Private Financing Supporting Pipeline of Next Generation Therapeutics for Solid Tumors...
Kura Oncology to Report Second Quarter 2025 Financial Results
SAN DIEGO, July 31, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing...
Plus Therapeutics Provides US Launch Update for its CNSide® Diagnostic
CNSide available for the state of Texas in August 2025 Initial commercial focus on NCI-Designated Cancer Centers and large private...
Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease
New clinical Precision Medicine population data demonstrates up to 84.6 Weeks (19.5 Months) ‘time saved’ by early-start ADAS-Cog13 difference: −5.43...